uniQure N.V. (NASDAQ:QURE) Ratings Coverage
In total 7 analysts cover uniQure NV (NASDAQ:QURE). “Buy” rating has 7, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 7 are the (NASDAQ:QURE)’s analyst reports since May 7, 2018 according to StockzIntelligence Inc. On Monday, September 24 the rating was maintained by H.C. Wainwright with “Buy”. On Wednesday, May 16 the firm has “Buy” rating by Wells Fargo given. On Wednesday, May 23 Chardan Capital Markets maintained uniQure N.V. (NASDAQ:QURE) rating. Chardan Capital Markets has “Buy” rating and $5000 target. On Monday, May 7 Leerink Swann maintained the shares of QURE in report with “Buy” rating. Listed here are uniQure N.V. (NASDAQ:QURE) PTs and latest ratings.
24/09/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $42 New Target: $48 Maintain
27/07/2018 Broker: Cantor Fitzgerald Rating: Overweight New Target: $58 Initiates Coverage On
28/06/2018 Broker: FBR Capital Rating: Buy New Target: $50 Initiates Coverage On
24/05/2018 Broker: SunTrust Rating: Buy New Target: $48 Initiates Coverage On
23/05/2018 Broker: Chardan Capital Markets Rating: Buy New Target: $50.0000 Maintain
16/05/2018 Broker: Wells Fargo Rating: Buy New Target: $47.0000 Initiate
07/05/2018 Broker: Leerink Swann Rating: Buy New Target: $63.0000 Maintain
Ticker’s shares touched $25.61 during the last trading session after 1.58% change.Currently uniQure N.V. is uptrending after 408.66% change in last November 5, 2017. QURE has also 96,967 shares volume. The stock outperformed the S&P 500 by 393.04%.
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands.The company has $953.86 million market cap. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington’s disease.Currently it has negative earnings. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency.
For more uniQure N.V. (NASDAQ:QURE) news released recently go to: Nasdaq.com, Nasdaq.com, Streetinsider.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “uniQure Announces Development of a Highly Potent, Next-Generation Promoter for Liver-Directed Gene Therapies” released on October 18, 2018, “uniQure to Host Research & Development Day on Monday, November 19 in New York City” on November 05, 2018, “uniQure (QURE) Highlights New Data Demonstrating Large-Scale Gene Therapy Manufacturing Capabilities” with a publish date: October 17, 2018, “Report: Exploring Fundamental Drivers Behind The Home Depot, uniQure NV, Catalent, Apple, BioTime, and PDL …” and the last “uniQure to Participate in Multiple Upcoming Industry Conferences” with publication date: October 31, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.